Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia

British Journal of Cardiology

Volumn 16, Issue 2, 2009, Pages 90-97

  Gleim, Gilbert ^a   Liu, Nancy ^a   Thompson Bell, Sally ^a   McCrary Sisk, Christine ^a   Pasternak, Richard C ^a   Mitchel, Yale ^a   Paolini, John F ^a   Ballantyne, Christie M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Extended release niacin; Laropiprant; Mixed hyperlipidaemia; Primary hypercholesterolaemia; Prostagandin D2; Simvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NIACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 65249130554     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006;103:6682-7.
3. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34.
4. Mills E, Prousky J, Raskin G et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003;3:4-11.
5. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50.
6. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979; 57:114-17.
7. Sturino CF, O'Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806.
8. Paolini JP, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol 2008;101:625-30.
9. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70.
10. The coronary drug project. JAMA 1972;221:918.
11. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
12. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study. Ann NY Acad Sci 1995; 748:407-17.
13. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
14. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
15. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98.
16. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary artery disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082-5.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-17.
18. Mack WJ, LaBree L, Liu C-R, Liu C-H, Selzer RH, Hodis HN. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 2000;150:371-9.
19. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99(Suppl):22C-31C.
20. Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805-07.
21. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77-81.
22. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes - results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76.
23. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 2000;284:1263-70.